For instance, mice deficient in either KIT or SCF lack tissue mast cells,4 and imatinib, a KIT kinase inhibitor, reduces mast cell number after long-term dosing in patients with chronic myelogenous leukemia.5 This evidence concerns the gene KIT and chronic myelogenous leukemia, BCR-ABL1 positive.